

Scott A Read

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/849496/publications.pdf>

Version: 2024-02-01

35
papers

1,193
citations

516710

16
h-index

434195

31
g-index

37
all docs

37
docs citations

37
times ranked

2224
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The Role of Zinc in Antiviral Immunity. <i>Advances in Nutrition</i> , 2019, 10, 696-710. | 6.4 | 497 |
| 2 | Virus induced inflammation and cancer development. <i>Cancer Letters</i> , 2014, 345, 174-181. | 7.2 | 74 |
| 3 | Zinc is a potent and specific inhibitor of IFN- λ 3 signalling. <i>Nature Communications</i> , 2017, 8, 15245. | 12.8 | 47 |
| 4 | The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. <i>Cells</i> , 2019, 8, 603. | 4.1 | 46 |
| 5 | Macrophage Coordination of the Interferon Lambda Immune Response. <i>Frontiers in Immunology</i> , 2019, 10, 2674. | 4.8 | 44 |
| 6 | The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. <i>Cells</i> , 2019, 8, 1324. | 4.1 | 39 |
| 7 | KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 71, 252-264. | 3.7 | 37 |
| 8 | The antiviral role of zinc and metallothioneins in hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 491-501. | 2.0 | 35 |
| 9 | Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. <i>Journal of General Virology</i> , 2014, 95, 1900-1910. | 2.9 | 32 |
| 10 | Adiponectin confers protection from acute colitis and restricts a B cell immune response. <i>Journal of Biological Chemistry</i> , 2017, 292, 6569-6582. | 3.4 | 32 |
| 11 | HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. <i>Gut</i> , 2021, 70, gutjnl-2019-319252. | 12.1 | 26 |
| 12 | Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. <i>Oncologist</i> , 2021, 26, e1216-e1225. | 3.7 | 26 |
| 13 | Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. <i>Journal of General Virology</i> , 2014, 95, 2468-2479. | 2.9 | 20 |
| 14 | Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 335-352. | 2.6 | 20 |
| 15 | Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 1030. | 2.4 | 20 |
| 16 | Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. <i>Genes and Immunity</i> , 2014, 15, 88-94. | 4.1 | 19 |
| 17 | Gastric Cancer Screening in Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018, 38, 768-777. | 3.8 | 18 |
| 18 | Examining the gut-liver axis in liver cancer using organoid models. <i>Cancer Letters</i> , 2021, 510, 48-58. | 7.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188350. | 7.4 | 16 |
| 20 | Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. <i>PLoS ONE</i> , 2015, 10, e0136227. | 2.5 | 16 |
| 21 | Non-coding RNA and immune-checkpoint inhibitors: friends or foes?. <i>Immunotherapy</i> , 2020, 12, 513-529. | 2.0 | 16 |
| 22 | Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. <i>Journal of Infectious Diseases</i> , 2021, 223, 1183-1195. | 4.0 | 14 |
| 23 | Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. <i>Cancers</i> , 2021, 13, 4345. | 3.7 | 13 |
| 24 | IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016, 17, 328-334. | 4.1 | 12 |
| 25 | Expansion of dysfunctional CD56 ⁺ CD16 ⁺ NK cells in chronic hepatitis B patients. <i>Liver International</i> , 2021, 41, 969-981. | 3.9 | 12 |
| 26 | The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 488-497. | 1.2 | 11 |
| 27 | Interferon- γ Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1257-1270. | 3.5 | 10 |
| 28 | Androgen deprivation in prostate cancer: benefits of home-based resistance training. <i>Sports Medicine - Open</i> , 2020, 6, 59. | 3.1 | 9 |
| 29 | Biostatics for high-throughput transformation and RNA interference in <i>Drosophila melanogaster</i> . <i>Fly</i> , 2008, 2, 247-254. | 1.7 | 8 |
| 30 | Targeting Gut-Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. <i>Livers</i> , 2021, 1, 147-179. | 1.9 | 3 |
| 31 | COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. <i>Vaccines</i> , 2022, 10, 889. | 4.4 | 3 |
| 32 | A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. <i>Livers</i> , 2022, 2, 97-104. | 1.9 | 1 |
| 33 | Pre-treatment predictors of immune-mediated hepatitis in non-small cell lung cancer patients treated with immune-checkpoint inhibitors: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e151136-e15136. | 1.6 | 0 |
| 34 | Landscape of immune-checkpoint inhibitors in hepatocellular carcinoma: A systematic review with meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16632-e16632. | 1.6 | 0 |
| 35 | 522...Transcriptomic changes in cancer patients treated with immune-checkpoint inhibitors. , 2021, 9, A552-A552. | | 0 |